Article (Scientific journals)
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Douxfils, Jonathan; Buckinx, Fanny; Mullier, Francois et al.
2014In Journal of the American Heart Association, 3 (3), p. 000515
Peer Reviewed verified by ORBi
 

Files


Full Text
Dabigatran Etexilate and Risk of Myocardial Infarction, Other.pdf
Publisher postprint (1.02 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
all‐cause mortality; dabigatran etexilate; major bleeding; myocardial infarction
Abstract :
[en] BACKGROUND: Signals of an increased risk of myocardial infarction (MI) have been identified with dabigatran etexilate in randomized controlled trials (RCTs). METHODS AND RESULES: We conducted searches of the published literature and a clinical trials registry maintained by the drug manufacturer. Criteria for inclusion in our meta-analysis included all RCTs and the availability of outcome data for MI, other cardiovascular events, major bleeding, and all-cause mortality. Among the 501 unique references identified, 14 RCTs fulfilled the inclusion criteria. Stratification analyses by comparators and doses of dabigatran etexilate were conducted. Peto odds ratio (ORPETO) values using the fixed-effect model (FEM) for MI, other cardiovascular events, major bleeding, and all-cause mortality were 1.34 (95% CI 1.08 to 1.65, P=0.007), 0.93 (95%CI 0.83 to 1.06, P=0.270), 0.88 (95% CI 0.79 to 0.99, P=0.029), and 0.89 (95% CI 0.80 to 1.00, P=0.041). When compared with warfarin, ORPETO values using FEM were 1.41 (95% CI 1.11 to 1.80, P=0.005), 0.94 (95%CI 0.83 to 1.06, P=0.293), 0.85 (95% CI 0.76 to 0.96, P=0.007), and 0.90 (95% CI 0.81 to 1.01, P=0.061), respectively. In RCTs using the 150-mg BID dosage, the ORPETO values using FEM were 1.45 (95% CI 1.11 to 1.91, P=0.007), 0.95 (95% CI 0.82 to 1.09, P=0.423), 0.92 (95% CI 0.81 to 1.05, P=0.228), and 0.88 (95% CI 0.78 to 1.00, P=0.045), respectively. The results of the 110-mg BID dosage were mainly driven by the RE-LY trial. CONCLUSIONS: This meta-analysis provides evidence that dabigatran etexilate is associated with a significantly increased risk of MI. This increased risk should be considered taking into account the overall benefit in terms of major bleeding and all-cause mortality.
Disciplines :
General & internal medicine
Author, co-author :
Douxfils, Jonathan
Buckinx, Fanny  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Mullier, Francois
Minet, Valentine
Rabenda, Véronique ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Hainaut, Philippe
Bruyère, Olivier  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Dogne, Jean-Michel
Language :
English
Title :
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Publication date :
2014
Journal title :
Journal of the American Heart Association
eISSN :
2047-9980
Publisher :
Wiley-Blackwell, United Kingdom
Volume :
3
Issue :
3
Pages :
e000515
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Available on ORBi :
since 10 June 2014

Statistics


Number of views
112 (34 by ULiège)
Number of downloads
5 (5 by ULiège)

Scopus citations®
 
94
Scopus citations®
without self-citations
94
OpenCitations
 
65

Bibliography


Similar publications



Contact ORBi